The Weston Brain Institute is launching three new funding programs:
Rapid Response: Canada 2018 (Alzheimer’s and Related Diseases)
Seed funding for novel, high-risk, high-reward translational research ideas to accelerate the development of safe and effective treatments for neurodegenerative diseases of aging. Applications in this round must relate to the following disease(s): AD, FTD, MCI, vascular contributions to these diseases, and prodromes to these diseases.
Funding Available: Up to $200,000 over up to 18 months
Eligibility: Principal applicants must be at or above the level of postdoctoral researcher at a CRA qualified institution located in Canada. Project must involve the development of a therapeutic, and/or a tool to help accelerate the development of therapeutics for neurodegenerative diseases of aging.
Program Information Session: March 8th, 2018 at 1pm EST (Register here)
Letter of Intent Deadline: April 19th, 2018 at 2pm EDT
Anticipated Award: October 2018
International Fellowships: Canada 2018
The goal of this new funding opportunity is to support top Canadian PhD students to travel to and work in world-renowned labs for up to 12 months during their PhD, and to further their translational research on neurodegenerative diseases of aging.
Funding Available: $60,000 per year, prorated at $5,000 per month to fit shorter travel and specific project needs.
Eligibility: Eligible applicants must be current PhD students at Canadian universities who are Canadian citizens or permanent residents. Applicants must be willing to travel to and conduct translational research on neurodegenerative disease(s) of aging while studying abroad in a world class laboratory.
Program Information Webinar #1: February 22nd, 2018, at 1pm EST (Register here)
Program Information Webinar #2: March 22nd, 2018, at 1:pm EDT (Register here)
Application Deadline: April 30th, 2018 at 2pm EDT
Anticipated Award: July 2018
International Outstanding Achievement Award 2018
Nominations are open for the third annual Weston Brain Institute International Outstanding Achievement Award. The award recognizes an investigator who, in the past 15 years, has made exceptional contributions, through translational research and leadership, to accelerating the development of therapeutics for neurodegenerative diseases of aging. The ideal candidate should also be active in research in the next 5 years, and have a record of impeccable citizenship in the research community.
In 2018, the award will be honoring an exceptional Canadian-based investigator working on neurodegenerative diseases of aging. The $40,000 prize will be presented during the Society for Neuroscience Annual Meeting (San Diego, CA)
Nomination Deadline: June 12, 2018
Award Ceremony: November 2018
Early Phase Clinical Trials: Canada 2018
The Early Phase Clinical Trials: Canada program was created to provide funding support for clinical trials and clinical trial sub-studies that have excellent preliminary data.
Funding Available: A maximum of $1,500,000 per project over up to 4 years
Eligibility: Principal applicants must be at or above the level of Assistant Professor or equivalent at a CRA qualified institution located in Canada. Project must involve the development of a therapeutic, and/or a tool to help accelerate the development of therapeutics for neurodegenerative diseases of aging. This program accepts applications on a rolling basis. Applicants may submit an LOI at any time and will be notified of whether to prepare a full Proposal within ~2 months of LOI submission.